// App-Quantinova.ai

: A Responder Analysis To Demonstrate Dupilumab Treatment Effect Across Objective and Patient-Reported Subjective Endpoints For Patients with Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Researchers

Presenter

  • Claus Bachert

Principal Investigators

  • Anju Peters

  • Enrico Heffler

  • Joseph Han

  • Heidi Olze

  • Oliver Pfaar

  • Chien-Chia Chuang

  • Raj Rout

  • Richa Attre

  • Ledia Goga

  • Juby Jacob-Nara

  • Paul Rowe

  • Yamo Deniz

  • Zhen Chen

  • Siddhesh Kamat

  • Shahid Siddiqui

Medical Centers

  • Ghent University Hospital, Ghent, Belgium

  • Allergy-Immunology Division and the Sinus and Allergy Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

  • Personalized Medicine, Asthma and Allergy ‐ Humanitas Clinical and Research Center, IRCCS, Milan, Italy

  • Eastern Virginia Medical School, Norfolk, VA

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

  • University Hospital Marburg, Phillipps University, Marburg, Germany

  • Sanofi, Cambridge, MA

  • Sanofi Genzyme, Reading, UK

  • Sanofi, Chilly-Mazarin, France

  • Sanofi, Bridgewater, NJ

Locations

  • Belgium

  • United States

  • Italy

  • Germany

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dupilumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved